Roquefort Therapeutics (ROQ) investor relations material

Transaction overview and strategic repositioning

• Acquisition of global rights to AO-252 for approximately £31.9m in shares, with a £8.5m placing to fund clinical programs and a £3m+ cornerstone commitment from A2A Pharmaceuticals and its directors.

• Transition to AIM trading under the new name Coiled Therapeutics plc, optimizing for clinical-stage value creation and shareholder returns.

• Management team brings deep expertise in biotech development, regulatory strategy, clinical execution, and capital markets.

Clinical asset and scientific rationale

• AO-252 is a brain-penetrant, orally available small molecule targeting TACC3, a validated but previously undruggable protein in precision oncology.

• Demonstrated strong preclinical efficacy with complete tumor regression in multiple solid tumor models, including brain metastases.

• Encouraging early Phase 1 clinical activity in ovarian and endometrial cancer patients, with a benign safety profile.

• Patient selection leverages biomarkers such as TP53 mutation, high centrosomal amplification, and elevated TACC3 expression.

Market opportunity and commercial strategy

• Addressable patient population of 350,000 across US and Europe, with a comparable market size of $20bn for similar oncology drugs.

• Ovarian and prostate cancers are primary targets for 2026, with plans to enroll 30-50 patients and generate comprehensive clinical data packages.

• Commercial strategy includes partnering with big pharma at the end of 2026, leveraging strong early interest from potential acquirers.